AMGEN INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 307.3 USD | +2.33% |
|
+12.18% | +6.70% |
| May. 08 | Mizuho Securities Raises Amgen's Price Target to $235 From $223 | MT |
| May. 06 | North American Morning Briefing : Stock Futures -2- | DJ |
ETFs positioned on Amgen Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.23% | 0 M€ | +6.12% | - | |
| 0.23% | 284 M€ | -.--% | ||
| 0.22% | 206 M€ | -.--% | ||
| 0.22% | 0 M€ | +6.03% | - | |
| 0.22% | 0 M€ | 0.00% | - | |
| 0.20% | 0 M€ | +8.21% | - | |
| 0.20% | 0 M€ | +4.60% | - | |
| 0.20% | 0 M€ | +0.78% | - | |
| 0.20% | 0 M€ | +4.60% | - | |
| 0.19% | 0 M€ | +7.77% | - | |
| 0.18% | 1 M€ | -.--% | ||
| 0.17% | 0 M€ | -1.48% | - | |
| 0.16% | 15 M€ | -1.62% | - | |
| 0.16% | 0 M€ | +3.22% | - | |
| 0.14% | 2 M€ | +3.16% | - | |
| 0.14% | 0 M€ | +5.23% | - | |
| 0.14% | 0 M€ | +4.96% | - | |
| 0.13% | 0 M€ | 0.00% | - | |
| 0.12% | 0 M€ | +11.38% | - | |
| 0.10% | 0 M€ | +2.68% | - |
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
300.3
USD
Average target price
313.3
USD
Spread / Average Target
+4.33%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +6.70% | 161B | |
| +32.95% | 700B | |
| -4.97% | 358B | |
| +18.83% | 330B | |
| +3.54% | 287B | |
| +15.70% | 236B | |
| +6.68% | 202B | |
| -9.08% | 197B | |
| -1.81% | 157B | |
| +3.70% | 124B |
- Stock Market
- Equities
- AMGN Stock
- Funds and ETFs Amgen Inc.